Tenvie Overview
- Year Founded
-
2024
- Status
-
Private
- Employees
-
48
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$200M
- Investors
-
4
Tenvie General Information
Description
Developer of small-molecule therapeutics intended to treat neurological and peripheral diseases. The company develops precision-engineered, brain-penetrant and peripherally restricted small-molecule therapies targeting neuroinflammation, metabolic dysfunction, and lysosomal function, enabling patients with neurological, cardiometabolic, and ophthalmic diseases to access novel treatment options.
Contact Information
Website
www.tenvie.comCorporate Office
- 1400 Sierra Point Parkway
- Suite 300
- Brisbane, CA 94005
- United States
Corporate Office
- 1400 Sierra Point Parkway
- Suite 300
- Brisbane, CA 94005
- United States
Tenvie Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 18-Dec-2024 | $200M | Completed | Clinical Trials - General |
Tenvie Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
Tenvie Patents
Tenvie Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026213354-A1 | Compounds, compositions, and methods | Pending | 02-Apr-2025 | ||
| WO-2026136648-A1 | Modulators of nlr family pyrin domain containing 3 and methods associated therewith | Pending | 19-Dec-2024 | ||
| WO-2025260014-A1 | Compounds, compositions, and methods | Pending | 14-Jun-2024 | ||
| WO-2025213088-A1 | Compounds, compositions, and methods | Pending | 05-Apr-2024 | ||
| EP-4794693-A1 | Compounds, compositions, and methods | Pending | 20-Oct-2023 | C07D401/12 |
Tenvie Signals
Tenvie Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARCH Venture Partners | Venture Capital | Minority | ||
| Eight Roads | Corporate Venture Capital | Minority | ||
| F-Prime | Venture Capital | Minority | ||
| Mubadala Capital | Asset Manager | Minority |
Tenvie FAQs
-
When was Tenvie founded?
Tenvie was founded in 2024.
-
Where is Tenvie headquartered?
Tenvie is headquartered in Brisbane, CA.
-
What is the size of Tenvie?
Tenvie has 48 total employees.
-
What industry is Tenvie in?
Tenvie’s primary industry is Drug Discovery.
-
Is Tenvie a private or public company?
Tenvie is a Private company.
-
What is the current valuation of Tenvie?
The current valuation of Tenvie is .
-
What is Tenvie’s current revenue?
The current revenue for Tenvie is .
-
How much funding has Tenvie raised over time?
Tenvie has raised $200M.
-
Who are Tenvie’s investors?
ARCH Venture Partners, Eight Roads, F-Prime, and Mubadala Capital have invested in Tenvie.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process